查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1857410

抗寄生虫药物市场（按药物类别和兽用划分）－2025年至2032年全球预测

Antiparasitic Drugs Market by Drug Class, Veterinary - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗寄生虫药物市场规模将达到 309.8 亿美元，复合年增长率为 4.90%。

关键市场统计数据
基准年 2024 211.2亿美元
预计年份：2025年 221.8亿美元
预测年份 2032 309.8亿美元
复合年增长率 (%) 4.90%

在临床和兽医领域全面推广抗寄生虫治疗，突显创新和管理的策略重点。

抗寄生虫治疗领域涵盖广泛且不断发展，包括科学创新、不断变化的监管环境以及兽医和临床护理中终端用户需求的转变。本导言透过描述主要药物类别、治疗用途以及影响产品开发和分销的商业性因素，确立了分析的范围。此外，本导言也将抗寄生虫药物置于一个相互关联的生态系统中，其中抗药性管理、製剂适应性和供应链韧性决定了其长期生存能力和临床相关性。

参与药物研发、生产和商业化的相关人员必须了解差异化治疗方法如何从分子创新中涌现，以及能够提升安全性、给药便利性和物种特异性疗效的製剂技术。此外，法律规范和药物管理计画对适应症扩展、仿单标示外用药考量和核准后义务的影响日益显着。因此，本导言旨在为报告的更广泛目标奠定基础：在科学、政策和市场快速变化的环境下，为循证优先排序、营运协调和跨职能决策提供策略基础。

有了这个通用的基准，接下来的章节将基于机制考虑和行业动态，确定哪些投资和合作能够带来最大价值，同时管理与韧性趋势和贸易相关中断有关的下行风险。

抗寄生虫药物研发和供应的策略转型：由分子创新、监管协调和基于诊断的管理所驱动

由于分子化学的进步、综合虫害管理理念的推广以及监管机构对抗药性防治日益重视，抗寄生虫药物领域正经历显着的变化。新型化合物类别和标靶製剂能够延长药效并提高安全性，而数位化工具的出现则进一步促进了诊断、监测和终端用户的用药依从性。因此，该行业正朝着精准抗寄生虫策略转型，优先考虑宿主特异性给药、环境管理和最大限度减少附带暴露。

同时，由于分销模式的改变以及对生技药品和联合治疗的日益重视，竞争格局正在改变。为了维持标籤价值并证明其高端定位的合理性，製造商正越来越多地整合生命週期管理策略，并纳入真实世界证据。同时，监管机构和产业之间也加强了合作，共同製定替代给药方案和新适应症的途径，从而缩短从创新到临床或兽医应用的时间。因此，能够将科学差异化、适应性监管策略和强大的市场推广能力相结合的公司，将最有优势引领下一波治疗药物的推广应用浪潮。

最后，这些因素的汇合促使相关人员重新思考传统的产品系列，优先考虑诊断相关治疗方法等综合提案主张，并投资于管理通讯协定，以维持治疗效用，同时满足兽医、生产者和饲主不断变化的期望。

对2025年美国关税将如何改变全球抗寄生虫药物产业的供应链设计、筹资策略和商业性定位进行全面评估

2025年美国关税的累积影响将为抗寄生虫药物供应链和商业策略带来复杂的贸易风险和营运调整。关税调整不仅会影响直接成本，还会影响采购决策、合约製造外包关係以及国内生产与海外生产的相对吸引力。因此，采购团队和业务规划人员正在重新评估供应商多元化和近岸外包方案，以降低关税波动带来的风险，并确保原料药和成品药的持续供应。

此外，关税波动会与外汇波动、运费波动和监管合规要求相互作用，加剧对到岸成本和库存策略的影响。因此，拥有全球企业发展的公司必须权衡集中式生产的规模优势和区域生产基地的弹性，后者能更好地吸收政策衝击。在实践中，这意味着要优先考虑策略采购、库存缓衝和双重采购安排，以确保关键零件的供应，同时在终端市场实现价格竞争。

除了生产製造和采购之外，关税也会影响商业策略。定价委员会、报销规划人员和合约负责人正在重新审视关于供应商长期承诺和经销伙伴的假设。他们也正在建构各种方案模型，包括付费生产合作关係以及在法规、劳动力和资本允许的情况下对国内产能进行策略性投资。总而言之，这些调整反映了现实世界的变化。企业正在将贸易政策情境纳入其企业风险管理，以确保在更广泛的外部环境下维持治疗方案的可及性和利润目标。

透过对药物类别和动物用药品子类别中机制差异进行深入的細項分析，从而指导药物开发、管理和商业化选择。

透过细緻的细分视角，我们可以揭示治疗药物类别和兽用应用如何影响研发重点和市场行为。药物类别包括氨基乙腈类（如莫能泮）、苯并咪唑类（如阿苯达唑、芬苯达唑、甲苯达唑、奥昔苯达唑和噻苯达唑）、苯并咪唑酮（如阿维菌素、多拉菌素、依普利菌素和伊维菌素）以及螺吲哚类（如德康特素）。每类药物的作用机制和安全性与有效性之间的权衡各不相同，从而决定了其首选应用场景。药物动力学和抗药性特征的差异使得某些类别的药物更适合特定的宿主物种和流行病学情况，进而影响製剂选择和管理通讯协定。

结合兽医细分市场，可以进一步精进战略意义。在水产养殖中，鱼虾是独立的生物和生产系统，因此治疗给药方式和环境影响等因素决定了活性成分的选择和给药方案。对于犬猫等伴侣动物，耐受性、给药便利性和饲主便利性是首要考虑因素，因此口服咀嚼片、局部製剂和长效注射剂等符合动物依从性的製剂更受青睐。在畜牧生产中，以牛、家禽和猪为目标，饲料和饮水相容性、停药期和养殖规模等因素会影响决策，生产者倾向于选择稳健、经济高效且能最大限度减少生产中断的解决方案。

因此，兼顾药物类别特性和兽药领域需求的综合产品策略优于一刀切的方法。研发蓝图应包含物种特异性安全性研究、针对特定生产系统特有的抗药性风险的管理计划，以及根据兽医和生产商的采购和管理实践量身定制的商业化策略。

亚太地区、欧洲以及中东和非洲的战略要务影响抗寄生虫产品的监管、分销和商业化优先事项。

拥有有效策略的公司对监管预期、分销网络和终端用户偏好具有强大的影响力，因此需要在关键区域采取差异化策略。在美洲，市场驱动因素包括成熟的兽医服务环境、较高的伴侣动物留存率以及优先考虑生产力和生物安全的先进畜牧生产系统。这些条件有利于创新配方和综合服务的推广，也为试点计画奠定了基础，这些试点计画能够在商业性实际条件下验证产品的功效和管理效果。

相反，欧洲、中东和非洲（EMEA）的管理体制和生产模式呈现出复杂多样的特点，有些地区监管标准严格，而有些地区则资源匮乏。因此，企业必须将全球统一的品质系统与在地化的註册策略相协调，并做好准备支援能力建构工作，以加强诊断能力，促进在不同环境下负责任地使用产品。此外，在该地区的部分地区，环境法规和社会监督提高了人们对残留物管理和生态系统影响的期望，这对产品设计和上市后监测都产生了影响。

亚太地区生产系统快速现代化，生物多样性丰富，监管环境复杂多样，因此既注重可扩展的生产，也重视可靠的安全性资料。该地区往往引领着高性价比学名药和替代剂型的普及，同时又为都市区伴侣动物市场的高级产品提供了机会。鑑于这些区域性特点，需要灵活的商业化模式，平衡区域伙伴关係、监管灵活性和有针对性的证据生成，以支持产品的持续推广应用。

企业动态和伙伴关係模式能够加速抗寄生虫药物创新，同时兼顾生命週期管理、供应弹性和监管义务。

活跃于抗寄生虫治疗领域的主要企业正在整合科学平台、拓展服务提案，并打破传统产品界限以伙伴关係。产业巨头正加大对製剂科学的投入，以提高产品的易用性和依从性，同时利用现场数据来展示疗效对比和管理成果。製药厂商、诊断公司和分销网络之间的策略联盟正在促成产品组合的推出，从而增强处方信心并巩固长期客户关係。

同时，拥有专注产品组合的中型创新企业正透过加速新型化合物的研发进度或拓展适应症以满足特定物种或生产系统中的未满足需求，从而掌握利基市场机会。这些公司通常利用策略授权合约和共同开发契约来扩大生产规模并更有效地拓展分销管道。此外，合约开发和受託製造公司也发挥关键作用，它们提供灵活的产能以支持快速进入市场，并促进供应链的地理多元化，从而应对贸易政策风险。

这种多元化的竞争格局凸显了跨职能协作的重要性，研发、监管和商业团队需要携手合作，以优化产品生命週期价值。那些将卓越技术与敏捷的伙伴关係模式结合的公司，最能掌握创新带来的长期效益，同时保持良好的产品管理和持续的供应保障。

为领导者提供行动建议，以协调创新、管理和贸易意识强的供应链策略，从而保护治疗价值和商业性韧性

产业领导者应优先考虑一系列切实可行的倡议，使科学创新与现实的商业性需求和监管环境相契合。首先，投资差异化製剂和伴随诊断将提升治疗价值，并支持实证应用。这种方法将透过降低仿单标示外风险和实现标靶治疗来加强监管。其次，将贸易政策情境规划纳入采购和生产策略将增强供应链韧性，使企业能够在不影响临床或兽医服务连续性的前提下，主动应对关税变化和运输中断。

第三，企业应将管理计画正式化，包括实地教育、抗药性监测以及与监管机构和从业人员透明的数据共用，从而维持长期有效性并维护品牌声誉。第四，在诊断、分销和契约製造建立策略伙伴关係，特别是结合以结果为导向、协调价值链各环节奖励的商业模式，可以加速市场进入并降低产能扩张的风险。最后，使商业性讯息与当地监管预期和终端用户行为相符，可以最大限度地提高市场准入率。这需要投资于针对特定市场的证据产生和量身定制的参与策略，以反映特定物种的监管实践和生产者的经济状况。

综合来看，这些行动构成了一个切实可行的蓝图，可以将科学进步转化为永续的、盈利的干预措施，从而在全球市场保持治疗效用并满足相关人员的期望。

我们采用透明的调查方法，结合专家访谈、监管机构审查和情境驱动分析，以确保提供可重复且可用于决策的情报。

本研究整合了一手和二手研究，建构了一个严谨、透明且可重复的分析基础。一手资料包括对药物发现、药品事务、兽医实践和商业性运营等领域的专家进行的结构化访谈，并辅以对同行评审文献和监管指导文件的技术性审查。二手研究则包括对公开文件、安全建议和已发布的抗药性监测报告进行评估性审查，以验证讯号并检验专家意见。

此分析方法结合了定性主题分析和基于情境的风险评估，旨在突显策略脆弱性和机会领域。透过比较案例研究，阐明了不同的管理体制和生产系统如何影响生命週期策略；并利用供应链图谱可视化了采购依赖关係和关税风险点。研究过程中，始终记录了调查方法的假设、资料来源和局限性，以确保结论具有情境性，并能应用于决策者的营运规划和投资组合优先顺序。

最后，我们与外部专家和内部相关人员进行了多次迭代检验会议，以完善我们的解释，并确保最终分析能够反映技术准确性和对研发、製造和商业领域使用者的实际相关性。

最终的综合分析强调，需要製定整合策略，在维持治疗效用的同时，平衡创新、管理和贸易韧性。

总之，抗寄生虫药物领域正处于曲折点，分子创新、不断变化的监管预期以及贸易政策压力正在重新定义研发者、製造商和经销商的战略重点。最成功的企业将是那些将差异化的科学方法与对管理、灵活的筹资策略以及反映物种特定政府和区域监管细微差别的本地化商业化计划相结合的企业。透过这样做，它们可以在伴侣动物、水产养殖和畜牧业领域开闢永续成长的新途径，同时保持治疗效果。

展望未来，持续投资于诊断、积极参与监管以及进行协作式管理对于维持长期治疗价值至关重要。那些果断采取行动，使其内部能力与外部现实（例如关税执法、抗药性监测和终端用户行为等）相适应的公司，将更有能力克服不确定性，并抓住不断变化的全球动态带来的机会。这项结论强调了製定整合策略规划的必要性，该规划应将洞察转化为贯穿产品生命週期和价值链的可衡量行动。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在开发中地区扩大以伊维菌素为基础的联合治疗在抗药性蠕虫病治疗的应用
  • 创新局部製剂可提高抗寄生虫药物的经皮渗透性，用于治疗疥疮
  • 扩大兽用抗寄生虫生技药品的使用范围，以预防牲畜寄生虫感染，进而减少农药残留。
  • 非洲大规模药物管理计划中对单剂量口服大环内酯类药物的需求日益增长
  • 新兴的奈米药物递送系统可提高抗寄生虫药物的疗效和患者依从性。
  • 增加数位诊断平台的投资，以便快速检测偏远地区的寄生虫感染

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的抗寄生虫药物市场

  • 氨基乙腈
    • 莫奈潘特
  • 苯并咪唑酮
    • 阿苯达唑
    • 芬苯达唑
    • 甲苯咪唑
    • 奥昔苯达唑
    • THIABENDAZOLE
  • 大环内酯
    • Avermectin
    • 多拉菌素
    • 依普利诺菌素
    • 伊维菌素
  • 螺吲哚
    • 德尔昆特尔

9. 兽用抗寄生虫药物市场

  • 水产养殖
    • 鱼
    • 虾
  • 伴侣动物
    • 狗
    • 猫
  • 家畜
    • 牛
    • 家禽
    • 猪

第十章 各地区抗寄生虫药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十一章 抗寄生虫药物市场（按类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十二章：各国抗寄生虫药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十三章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • Bayer AG
    • Ceva Sante Animale SA
    • Virbac SA
    • Dechra Pharmaceuticals PLC
    • Vetoquinol SA
    • Norbrook Laboratories Limited
Product Code: MRR-B16853777759

The Antiparasitic Drugs Market is projected to grow by USD 30.98 billion at a CAGR of 4.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.12 billion
Estimated Year [2025] USD 22.18 billion
Forecast Year [2032] USD 30.98 billion
CAGR (%) 4.90%

Comprehensive introduction framing antiparasitic therapeutics across clinical and veterinary domains while highlighting strategic priorities for innovation and stewardship

The landscape of antiparasitic therapeutics encompasses a broad and evolving combination of scientific innovation, regulatory change, and shifting end-user needs across veterinary and clinical care. This introduction establishes the scope of analysis by contextualizing core drug classes, therapeutic applications, and the commercial imperatives that shape product development and distribution. It situates antiparasitic agents within an interconnected ecosystem where resistance management, formulation adaptability, and supply chain resilience determine long-term viability and clinical relevance.

Stakeholders operating in discovery, manufacturing, and commercialization should understand how therapeutic differentiation emerges from molecular innovation as well as from formulation technologies that improve safety, dosing convenience, and species-specific efficacy. In addition, regulatory frameworks and stewardship programs increasingly influence label expansions, off-label use considerations, and post-approval obligations. Consequently, this introduction frames the report's broader objective: to provide a strategic foundation that supports evidence-based prioritization, operational alignment, and cross-functional decision-making in an environment of accelerating scientific, policy, and market change.

By establishing this common baseline, the subsequent sections build on mechanistic considerations and sectoral dynamics to reveal where investments and collaborations will deliver the highest value while managing downside risks associated with resistance trends and trade-related disruptions.

Strategic transformation in antiparasitic development and delivery driven by molecular innovation, regulatory alignment, and diagnostic-enabled stewardship

The antiparasitic landscape is undergoing transformative shifts driven by advances in molecular chemistry, integrated pest management philosophies, and a heightened regulatory focus on resistance mitigation. New compound classes and targeted formulations are enabling longer durations of efficacy and improved safety profiles, and this scientific progress is being complemented by digital tools that improve diagnosis, monitoring, and adherence across end users. Consequently, the industry is moving toward precision antiparasitic strategies that prioritize host-specific dosing, environmental stewardship, and minimized collateral exposure.

At the same time, changes in distribution models and an expanding emphasis on biologics and combination therapies are altering competitive dynamics. Manufacturers are increasingly integrating lifecycle management strategies that incorporate real-world evidence to sustain label value and justify premium positioning. This shift is occurring in parallel with more proactive collaboration between regulators and industry to define pathways for alternative dosing regimens and novel indications, thereby shortening the time from innovation to clinical or veterinary adoption. As a result, companies that can combine scientific differentiation with adaptive regulatory strategies and strong field-level engagement will be best positioned to lead the next wave of therapeutic uptake.

Finally, the confluence of these factors encourages stakeholders to rethink traditional product portfolios, prioritize integrated value propositions such as diagnostic-linked therapies, and invest in stewardship protocols that preserve therapeutic utility while meeting evolving expectations from veterinarians, producers, and pet owners.

Comprehensive evaluation of how United States tariff measures in 2025 reshape supply chain design, procurement strategy, and commercial positioning across global antiparasitic operations

The cumulative impact of United States tariff actions in 2025 introduces a complex layer of trade-related risk and operational recalibration for antiparasitic supply chains and commercial strategies. Tariff adjustments have ripple effects beyond direct cost implications: they influence sourcing decisions, contract manufacturing relationships, and the relative attractiveness of domestic versus international production. In turn, procurement teams and business planners are reassessing supplier diversification and nearshoring options to mitigate exposure to tariff volatility and to maintain continuity of supply for both active pharmaceutical ingredients and finished formulations.

Moreover, tariff dynamics interact with currency movements, freight cost variability, and regulatory compliance requirements, producing compound effects on landed costs and inventory policies. Companies with global footprints must therefore balance the benefits of centralized manufacturing scale against the flexibility of regional production nodes that can absorb policy shocks more readily. In practice, this means that strategic procurement, inventory buffering, and dual-sourcing agreements are being prioritized to preserve access to critical components while enabling price competitiveness in end markets.

Beyond manufacturing and procurement, tariffs also affect commercial strategy. Pricing committees, reimbursement planners, and contract negotiators are revisiting assumptions about long-term supplier commitments and distribution partnerships. They are also modeling pathway options that include toll-manufacturing relationships and strategic investments in domestic capacity where regulatory, labor, and capital considerations permit. Taken together, these adjustments reflect a pragmatic shift: organizations are embedding trade-policy scenarios into enterprise risk management to ensure that therapeutic availability and margin objectives are maintained under a wider range of external conditions.

Insightful segmentation analysis that interrelates drug-class mechanistic differences with veterinary subcategories to drive development, stewardship, and commercialization choices

A nuanced segmentation lens clarifies how therapeutic class and veterinary application jointly shape development priorities and market behavior. Drug class segmentation spans Amino-Acetonitrile chemistries such as Monepantel, Benzimidazoles including Albendazole, Fenbendazole, Mebendazole, Oxibendazole, and Thiabendazole, Macrocyclic Lactones represented by Abamectin, Doramectin, Eprinomectin, and Ivermectin, as well as Spiroindoles exemplified by Derquantel, each bringing distinct mechanisms of action and safety-efficacy trade-offs that determine preferred use cases. Differences in pharmacokinetics and resistance profiles make certain classes more suitable for particular host species and epidemiological contexts, thereby influencing formulation choices and stewardship protocols.

Overlaying this with veterinary segmentation further refines strategic implications. In aquaculture, where fish and shrimp represent separate biological and production systems, treatment delivery methods and environmental impact considerations dictate the selection of active ingredients and dosing regimens. Companion animal contexts such as canine and feline care prioritize tolerability, ease of administration, and owner convenience, which favors oral chewables, topical formulations, and long-acting injectables that align with adherence behaviors. In livestock contexts covering cattle, poultry, and swine, decision drivers include feed and water compatibility, withdrawal periods, and operational scale, with producers favoring robust, cost-efficient solutions that minimize production disruption.

Consequently, integrated product strategies that consider both drug-class attributes and veterinary segment needs will outperform one-size-fits-all approaches. Development roadmaps should incorporate species-specific safety studies, stewardship plans that address resistance risks endemic to particular production systems, and commercialization tactics tailored to the procurement and administration practices of veterinarians and producers.

Regional strategic imperatives across Americas, Europe Middle East & Africa, and Asia-Pacific that shape regulatory, distribution, and commercialization priorities for antiparasitic products

Regional dynamics exert strong influence on regulatory expectations, distribution networks, and end-user preferences, requiring differentiated strategies across major geographies. In the Americas, market drivers are shaped by a mature veterinary services environment, high companion animal ownership rates, and advanced livestock production systems that prioritize productivity and biosecurity. These conditions favor innovative formulations and integrated service offerings, and they also create a platform for pilot programs that demonstrate efficacy and stewardship outcomes under commercially realistic conditions.

Conversely, Europe, Middle East & Africa present a mosaic of regulatory regimes and production modalities, with stringent regulatory standards in some jurisdictions and resource-constrained environments in others. Consequently, companies must reconcile uniform global quality systems with locally adapted registration strategies, and they must be prepared to support capacity-building efforts that enhance diagnostic capability and responsible use in diverse settings. In addition, environmental regulations and public scrutiny in parts of this region heighten expectations around residue control and ecological impact, influencing both product design and post-market surveillance.

The Asia-Pacific region combines rapidly modernizing production systems with high biodiversity and varied regulatory landscapes, prompting a dual focus on scalable manufacturing and robust safety data. This region often leads in adoption of cost-effective generics and alternative delivery formats, while simultaneously presenting opportunities for differentiated, premium products in urban companion-animal markets. Together, these regional contingencies necessitate flexible commercialization models that balance local partnerships, regulatory agility, and targeted evidence generation to support sustained uptake.

Corporate dynamics and partnership models that accelerate antiparasitic innovation while balancing lifecycle management, supply resilience, and stewardship obligations

Leading companies active in antiparasitic therapeutics are consolidating scientific platforms, expanding service propositions, and forming partnerships that extend beyond traditional product boundaries. Industry incumbents are investing in formulation science to enhance ease of use and compliance, while simultaneously leveraging field-level data to demonstrate comparative performance and stewardship outcomes. Strategic alliances between pharmaceutical manufacturers, diagnostic firms, and distribution networks are enabling bundled offerings that improve prescribing confidence and strengthen long-term customer relationships.

At the same time, mid-sized innovators with focused portfolios are capitalizing on niche opportunities by accelerating development timelines for new chemical entities and by pursuing label expansions that address unmet needs in specific species or production systems. These companies often rely on strategic licensing and co-development agreements to scale manufacturing and access distribution channels more efficiently. Meanwhile, contract development and manufacturing organizations are playing a critical role by providing flexible capacity that supports rapid market entry and by enabling geographic diversification of supply chains to manage trade-policy exposure.

Collectively, this competitive landscape emphasizes the importance of cross-functional collaboration, where R&D, regulatory affairs, and commercial teams coordinate to optimize lifecycle value. Companies that combine technical excellence with agile partnership models will be best positioned to capture the long-term benefits of innovation while maintaining robust stewardship and supply continuity.

Actionable recommendations for leaders to align innovation, stewardship, and trade-aware supply chain strategies to protect therapeutic value and commercial resilience

Industry leaders should prioritize a set of actionable initiatives that align scientific innovation with practical commercial imperatives and regulatory realities. First, investing in differentiated formulations and companion diagnostics will increase therapeutic value and support evidence-based adoption; this approach reduces off-label risks and strengthens stewardship by enabling targeted treatment. Second, embedding trade-policy scenario planning into procurement and manufacturing strategies will enhance supply chain resilience, allowing organizations to respond proactively to tariff shifts and transport disruptions without disrupting clinical and veterinary continuity.

Third, companies should formalize stewardship programs that include field-level education, resistance monitoring, and transparent data sharing with regulators and practitioners, thereby preserving long-term efficacy and protecting brand reputation. Fourth, strategic partnerships across diagnostics, distribution, and contract manufacturing can accelerate market access and de-risk capacity expansion, particularly when combined with outcome-driven commercial models that align incentives across the value chain. Finally, aligning commercial messaging with local regulatory expectations and end-user behaviors will maximize uptake; this requires investment in market-specific evidence generation and tailored engagement strategies that reflect species-specific administration practices and producer economics.

Taken together, these actions form a practical roadmap for translating scientific advances into sustainable, profitable interventions that maintain therapeutic utility and meet stakeholder expectations across global markets.

Transparent research methodology combining expert interviews, regulatory review, and scenario-driven analysis to ensure reproducible and decision-ready intelligence

This research synthesizes primary and secondary evidence to produce a rigorous, transparent, and reproducible analytical foundation. Primary inputs included structured interviews with subject-matter experts across discovery, regulatory affairs, veterinary practice, and commercial operations, complemented by technical reviews of peer-reviewed literature and regulatory guidance documents. Secondary research encompassed an evaluative review of public filings, safety advisories, and published resistance surveillance reports to triangulate signals and validate expert perspectives.

Analytical methods combined qualitative thematic analysis with scenario-based risk assessment to surface strategic vulnerabilities and opportunity areas. Comparative case studies were used to illustrate how different regulatory regimes and production systems shape lifecycle strategies, while supply chain mapping provided visibility into sourcing dependencies and tariff exposure points. Throughout, care was taken to document assumptions, data provenance, and methodological limitations, ensuring that conclusions are contextualized and actionable for decision-makers seeking to apply the findings to operational planning and portfolio prioritization.

Finally, iterative validation sessions with external experts and internal stakeholders were conducted to refine interpretations and ensure that the final analysis reflects both technical accuracy and practical relevance for users across R&D, manufacturing, and commercial functions.

Final synthesis highlighting the imperative for integrated strategies that preserve therapeutic utility while aligning innovation, stewardship, and trade resilience

In conclusion, the antiparasitic domain is at an inflection point where molecular innovation, shifting regulatory expectations, and trade-policy pressures converge to redefine strategic priorities for developers, manufacturers, and distributors. The most successful organizations will be those that integrate differentiated scientific approaches with stewardship commitments, resilient sourcing strategies, and localized commercialization plans that reflect species-specific administration and regional regulatory nuances. By doing so, they will preserve therapeutic efficacy while unlocking new avenues for sustainable growth across companion animal, aquaculture, and livestock sectors.

Looking ahead, continued investment in diagnostics, adaptive regulatory engagement, and collaborative stewardship will be essential to maintain long-term therapeutic value. Companies that act decisively to align internal capabilities with external realities-particularly around tariff exposure, resistance surveillance, and end-user behavior-will be better equipped to navigate the uncertainties and capture opportunities presented by evolving global dynamics. This conclusion underscores the imperative for integrated strategic planning that translates insight into measurable actions across the product lifecycle and the value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of ivermectin-based combination therapies for resistant helminthiasis in developing regions
  • 5.2. Innovative topical formulations improving dermal penetration of antiparasitic agents for scabies treatment
  • 5.3. Expansion of veterinary antiparasitic biologics targeting livestock parasite prevention to reduce chemical residues
  • 5.4. Rising demand for single-dose oral macrocyclic lactone drugs in mass drug administration programs across Africa
  • 5.5. Emergence of nanoformulation delivery systems enhancing antiparasitic drug efficacy and patient compliance
  • 5.6. Increasing investments in digital diagnostic platforms for rapid detection of parasitic infections in remote areas

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiparasitic Drugs Market, by Drug Class

  • 8.1. Amino-Acetonitrile
    • 8.1.1. Monepantel
  • 8.2. Benzimidazoles
    • 8.2.1. Albendazole
    • 8.2.2. Fenbendazole
    • 8.2.3. Mebendazole
    • 8.2.4. Oxibendazole
    • 8.2.5. Thiabendazole
  • 8.3. Macrocyclic Lactones
    • 8.3.1. Abamectin
    • 8.3.2. Doramectin
    • 8.3.3. Eprinomectin
    • 8.3.4. Ivermectin
  • 8.4. Spiroindoles
    • 8.4.1. Derquantel

9. Antiparasitic Drugs Market, by Veterinary

  • 9.1. Aquaculture
    • 9.1.1. Fish
    • 9.1.2. Shrimp
  • 9.2. Companion Animals
    • 9.2.1. Canine
    • 9.2.2. Feline
  • 9.3. Livestock
    • 9.3.1. Cattle
    • 9.3.2. Poultry
    • 9.3.3. Swine

10. Antiparasitic Drugs Market, by Region

  • 10.1. Americas
    • 10.1.1. North America
    • 10.1.2. Latin America
  • 10.2. Europe, Middle East & Africa
    • 10.2.1. Europe
    • 10.2.2. Middle East
    • 10.2.3. Africa
  • 10.3. Asia-Pacific

11. Antiparasitic Drugs Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. Antiparasitic Drugs Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Analysis
    • 13.3.1. Zoetis Inc.
    • 13.3.2. Merck & Co., Inc.
    • 13.3.3. Boehringer Ingelheim International GmbH
    • 13.3.4. Elanco Animal Health Incorporated
    • 13.3.5. Bayer AG
    • 13.3.6. Ceva Sante Animale S.A.
    • 13.3.7. Virbac S.A.
    • 13.3.8. Dechra Pharmaceuticals PLC
    • 13.3.9. Vetoquinol S.A.
    • 13.3.10. Norbrook Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASEAN ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GCC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPEAN UNION ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. BRICS ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. G7 ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NATO ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. ANTIPARASITIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. ANTIPARASITIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIPARASITIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD